Estimates of HIV-1 incidence based on serological methods: A brief methodological review;Estimativas de incidência da infecção pelo HIV-1 baseadas em métodos sorológicos: Uma sumária revisão metodológica

Cadernos de Saude Publica

Volumn 27, Issue SUPPL. 1, 2011, Pages

  Morgado, Mariza Gonçalves ^a   Bastos, Francisco Inácio ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Fundação Oswaldo Cruz   (Brazil)

Author keywords

HIV infections; HIV 1; Incidence

Indexed keywords

BRAZIL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INCIDENCE; METHODOLOGY; REVIEW; SEROLOGY;

BRAZIL; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INCIDENCE; SEROLOGIC TESTS;

EID: 79955672517     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2011001300002     Document Type: Review

References (69)

1. Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2008.
2. Bastos FI, Nunn A, Hacker MA, Malta M, Szwarcwald CL. AIDS in Brazil: the challenge and the response. In: Celentano DD, Beyrer C, editors. Public health aspects of HIV/AIDS in developing countries: epidemiology, prevention and care. New York: Springer International; 2008. p. 629-654.
3. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
4. Bätzing-Feigenbaum J, Loschen S, Gohlke-Micknis S, Zimmermann R, Herrmann A, Kamga Wambo O, et al. Country-wide HIV incidence study complementing HIV surveillance in Germany. Euro Surveill 2008; 13:pii:18971.
5. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
6. MACS celebrates its 25th anniversary. AIDS Patient Care STDS 2009; 23:486-487.
7. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28:351-357.
8. Nelson KE, Vlahov D, Solomon L, Cohn S, Muñoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med 1995; 155:1305-1311.
9. Harrison L, Dunn DT, Green H, Copas AJ. Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med 2009; 28:3260-3275.
10. Brookmeyer R. Should biomarker estimates of HIV incidence be adjusted? AIDS 2009; 23:485-491.
11. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91-97.
12. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254-264.
13. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995; 141:166-172.
14. Miettinen OS. Theoretical epidemiology. New York: John Wiley & Sons; 1985.
15. Bastos FI. "Get back to where you once belonged": monitoring the AIDS pandemic in the 21st century. Cien Saúde Coletiva 2008; 13:1719-1727.
16. Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res 2005; 121:510-518.
17. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008; 13:pii:18966.
18. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48.
19. Parekh BS, Hu DJ, Vanichseni S, Satten GA, Candal D, Young NL, et al. Evaluation of a sensitive/ less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses 2001; 17:453-458.
20. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, Nelson R, et al. Evaluation of a sensitive/less sensitive testing algorithm using the bioMérieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses 2003; 19:481-486.
21. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002; 18:295-307.
22. Hu DJ, Vanichseni S, Mock PA, Young NL, Dobbs T, Byers Jr. RH, et al. HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS Res Hum Retroviruses 2003; 19:727-730.
23. Nesheim S, Parekh B, Sullivan K, Bulterys M, Dobbs T, Lindsay M, et al. Temporal trends in HIV type 1 incidence among inner-city childbearing women in Atlanta: use of the IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 2005; 21:537-544.
24. Wolday D, Meles H, Hailu E, Messele T, Mengistu Y, Fekadu M, et al. Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia, 1995-2003. J Intern Med 2007; 261:132-137.
25. Priddy FH, Pilcher CD, Moore RH, Tambe P, Park MN, Fiscus SA, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007; 44:196-202.
26. Mermin J, Musinguzi J, Opio A, Kirungi W, Ekwaru JP, Hladik W, et al. Risk factors for recent HIV infection in Uganda. JAMA 2008; 300:540-549.
27. UNAIDS Reference Group on estimates, modeling and projections - statement on the use of the BED assay for the estimation of HIV-1 incidence for surveillance or epidemic monitoring. Wkly Epidemiol Rec 2006; 81:40.
28. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using crosssectional and longitudinal seroconverter specimens from Africa. AIDS 2007; 21:403-408.
29. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, Ackers M, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by crosssectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22:945-952.
30. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, Ntozini R, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 2008; 22:511-518.
31. Le Guillou H, Le Meur A, Bourdon S, Riou M, Loison J, Fialaire P, et al. Avidité des anticorps: application au diagnostic d'infection récente à VIH1. Ann Biol Clin (Paris) 2001; 59:41-47.
32. Suligoi B, Galli C, Massi M, Di Sora F, Sciandra M, Pezzotti P, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassaybased method. J Clin Microbiol 2002; 40:4015-4020.
33. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003; 32:424-428.
34. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, Parry JV, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007; 45:415-420.
35. Gupta SB, Murphy G, Koenig E, Adon C, Beyrer C, Celentano D, et al. Comparison of methods to detect recent HIV type 1 infection in cross-sectionally collected specimens from a cohort of female sex workers in the Dominican Republic. AIDS Res Hum Retroviruses 2007; 23:1475-1480.
36. Suligoi B, Buttò S, Galli C, Bernasconi D, Salata RA, Tavoschi L, et al. Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol 2008; 41:288-292.
37. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 2004; 18:2253-2259.
38. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005; 43:4441-4447.
39. Semaille C, Cazein F, Pillonel J, Lot F, Le Vu S, Pinget R, et al. Four years of surveillance of recent HIV infections at country level, France, mid 2003 - 2006: experience and perspectives. Euro Surveill 2008; 13:pii:18968.
40. Sakarovitch C, Rouet F, Murphy G, Minga AK, Alioum A, Dabis F, et al. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007; 45:115-122.
41. Schüpbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, Bürgisser P, et al. Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 2007; 4:e343.
42. Schechter M, Lago RF, Melo MF, Sheppard HW, Guimarães NC, Moreira RI, et al. Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praça Onze Study Group. J Acquir Immune Defic Syndr 2000; 24:175-177.
43. Barroso PF, Harrison LH, Fátima-Melo M, Batista SM, Silva-Bastos M, Rosa-Faulhaber JC, et al. Identification of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil, using a sensitive/less-sensitive assay: an update. J Acquir Immune Defic Syndr 2004; 36:880-881.
44. Guimarães ML, Bastos FI, Telles PR, Galvão-Castro B, Diaz RS, Bongertz V, et al. Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II. J Clin Virol 2001; 21:143-151.
45. Teixeira SL, Bastos FI, Telles PR, Hacker MA, Brigido LF, Oliveira CAF, et al. HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol 2004; 31:221-226.
46. Diaz RS, Kallas EG, Castelo A, Rawal BD, Busch MP. Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing. AIDS 1999; 13:1417-1418.
47. Turchi MD, Diaz RS, Martelli CM, Sabino EC, Silva WP, Filho OF, et al. Genetic diversity and HIV-1 incidence estimation among cocaine users in São Paulo, Brazil. J Acquir Immune Defic Syndr 2002; 30:527-532.
48. Alves K, Shafer KP, Caseiro M, Rutherford G, Falcao ME, Sucupira MC, et al. Risk factors for incident HIV infection among anonymous HIV testing site clients in Santos, Brazil: 1996-1999. J Acquir Immune Defic Syndr 2003; 32:551-559.
49. Kallas EG, Bassichetto KC, Oliveira SM, Goldenberg I, Bortoloto R, Moreno DM, et al. Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of São Paulo, Brazil. Braz J Infect Dis 2004; 8:399-406.
50. Bassichetto KC, Bergamaschi DP, Veras MA, Sucupira MC, Mesquita F, Diaz RS. Estimating HIV-1 incidence using the serologic testing algorithm for recent HIV infections at HIV counseling and testing centers in the city of São Paulo, Brazil. Braz J Infect Dis. 2009; 13:9-12.
51. Freitas-Oliveira CA, Ueda M, Yamashiro R, Rodrigues R, Sheppard HW, Macedo-Brígido LF. Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in São Paulo, Brazil, from 1991 to 2002. J Clin Microbiol 2005; 43:1439-1442.
52. Barreto CC, Sabino EC, Gonçalez TT, Laycock ME, Pappalardo BL, Salles NA, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion 2005; 45:1709-1714.
53. Sá-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, Morgado MG. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors. Transfusion 2007; 47:97-102.
54. de Castro CA, Grinsztejn B, Veloso VG, Bastos FI, Pilotto JH, Morgado MG. Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brasil. BMC Infect Dis 2010; 10:224.
55. Ferreira JL, Thomaz M, Rodrigues R, Harrad D, Oliveira CM, Oliveira CA, et al. Molecular characterization of newly identified HIV-1 infections in Curitiba, Brazil: preponderance of clade C among males with recent infections. Mem Inst Oswaldo Cruz 2008; 103:800-808.
56. Brígido LF, Nunes CC, Oliveira CM, Knoll RK, Ferreira JL, Freitas CA, et al. HIV type 1 subtype C and CB Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS Res Hum Retroviruses 2007; 23:1579-1586.
57. Velasco-de-Castro CA, Grinsztejn B, Veloso V, Bastos F, Pilotto J, Morgado M. Serological approaches to access recent HIV-1 seroconvertion: proposal of criterion to improve the predictive values in BEDCEIA and Avidity Index Assay. AIDS Res Hum Retrov 2008; 24 Suppl 1:S36.
58. Hargrove JW. BED estimates of HIV incidence must be adjusted. AIDS 2009; 23:2061-2062.
59. Welte A, McWalter TA, Bärnighausen T. Reply to 'Should biomarker estimates of HIV incidence be adjusted?'. AIDS 2009; 23:2062-2063.
60. McDougal JS. BED estimates of HIV incidence must be adjusted. AIDS 2009; 23:2064-2065.
61. Brookmeyer R. Response to correspondence on 'Should Biomarker Estimates of HIV Incidence be Adjusted?'. AIDS 2009; 23:2066-2068.
62. McWalter TA, Welte A. A comparison of biomarker based incidence estimators. PLoS One 2009; 4:e7368.
63. Hallett TB, Ghys P, Bärnighausen T, Yan P, Garnett GP. Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One 2009; 4:e5720.
64. Truong HH, Kellogg T, Louie B, Klausner J, Dilley J, McFarland W. Recent HIV-1infection detection: comparison of incidence estimates derived by laboratory assays and repeat testing data. J Acquir Immune Defic Syndr 2009; 51:502-505.
65. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus CK, et al. The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins hospital emergency department. J Acquir Immune Defic Syndr 2008; 48:211-215.
66. Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, et al. Immune activation and antibody responses in nonprogressing elite controller individuals infected with HIV-1. J Med Virol 2009; 81:1681-1690.
67. World Health Organization. Report of the WHO working group on statistical approaches for development, validation and use of HIV incidence assays. http://www.who.int/diagnostics_laboratory/links/hiviwg_geneva_04_09_repo rt.pdf (accessed on Apr/2009).
68. Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI. Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med 2008; 27:4617-4633.
69. Hacking I. The taming of chance (ideas in context). Cambridge: Cambridge University Press; 1990.